Celgene, Gilead Sciences shares could rise 30 percent: Barron's

NEW YORK (Reuters) - The tumble in share prices for biotechnology stocks has created some buying opportunities, with drugmakers Celgene Corp and Gilead Sciences poised for a 30 percent rise over the next year, Barron's said.

http://ift.tt/1Sa8uRX

from Reuters: Health News
via animenewspro